



## **EUDRACT SUMMARY REPORT FOR STUDY 2012-003735-32**

### **Statement of Early Termination:**

This study was discontinued by AB Science during preparation of the trial. No patient entered the study; therefore, no results/data are available.

**Protocol Number:** AB11005

**EudraCT Number:** 2012-003735-32

**Name of Test Drug:** Masitinib (AB1010)

**Indication:** Relapsing remitting multiple sclerosis

**Study Title:** A 96-weeks, prospective, multicentre, randomised, open label, active-controlled, parallel groups, phase 2b/3 study to compare efficacy and safety of masitinib to first line treatment, in patients with relapsing remitting multiple sclerosis with unsatisfactory response to first line treatment.

**Phase:** 2b/3

**Study Period:** Not Applicable

**Centres:** Not Applicable

**Number of Subjects:** 0 (zero)

**Publications:** Not Applicable

**Sponsor:** AB Science

**Public Contact:** Clinical Study Coordinator, AB Science, [clinical@ab-science.com](mailto:clinical@ab-science.com)